Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 28Radiotherapy 20pembrolizumab 9Paclitaxel 9Surveys and Questionnaires 8Cetuximab 8Fluorouracil 7Docetaxel 7Radiotherapy, Intensity-Modulated 6Carboplatin 6apatinib 5Low-Level Light Therapy 5Blood Specimen Collection 5durvalumab 4Standard of Care 4Magnetic Resonance Imaging 4Gemcitabine 4Cyclophosphamide 4Celecoxib 4Tegafur 3Radiation 3Oncolytic Virotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lidocaine 3Immunoenzyme Techniques 3Drug Therapy 3Chemotherapy, Adjuvant 3Biopsy 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Head and Neck Neoplasms × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡